REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Total net revenues	$ 148,332	$ 131,829	$ 423,802	$ 355,162
Total sales of rare disease pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	56,426	29,734	142,556	70,368
Sales of Cortrophin Gel
Disaggregation of Revenue [Line Items]
Total net revenues	52,555	29,734	138,685	70,368
Sales of ILUVIEN and YUTIQ
Disaggregation of Revenue [Line Items]
Total net revenues	3,871	0	3,871	0
Total sales of generic and established brand pharmaceutical products, royalties, and other pharmaceuticals services
Disaggregation of Revenue [Line Items]
Total net revenues	91,906	102,095	281,246	284,794
Sales of generic pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	78,223	70,593	222,404	197,623
Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services
Disaggregation of Revenue [Line Items]
Total net revenues	$ 13,683	$ 31,502	$ 58,842	$ 87,171